Objective: To determine midazolam pharmacokinetics in healthy Mexican volunteers and to
compare them with the pharmacokinetics reported for other populations. Patients and …

What is known and Objectives: Subjects of different ethnic groups may respond differently to
drugs. The present study was conducted to compare the oral pharmacokinetics of …

Abstract Background and Objective Midazolam is the preferred clinical probe drug for
assessing CYP3A activity. We have previously shown substantial intraindividual variability in …

Objective To investigate putative differences in CYP3A activity between European American
and Japanese subjects using midazolam as an in vivo probe. Methods Midazolam was …

The first‐dose pharmacokinetics of midazolam and its primary α‐hydroxy metabolite were
studied after single‐dose administration. Eligible study patients were enrolled into one of …

The pharmacokinetics of midazolam and 1-hydroxymethylmidazolam were investigated
following oral administration of 7.5, 15 and 30 mg doses of midazolam in solution to 12 …

Aims Midazolam has good anxiolytic qualities and is a well established premedication agent
before anaesthesia or short surgical procedures. The objective of the present study was to …

A serum concentration profile study on midazolam in children was done. Fifty six children
aged 3–10 years took part. The routes investigated were intravenous, intramuscular, rectal …

The CYP3A subfamily represents the most abundant cytochrome P450 in the human liver
and gastrointestinal tract and plays very important role in xenobiotic metabolism. CYP3A5 is …

Aim To find out a single plasma sampling to estimate oral clearance of midazolam (MDZ)
and CYP3A activity, and explore the pharmacokinetics of midazolam hydroxylation in …